{"id":17915,"date":"2024-02-06T12:31:11","date_gmt":"2024-02-06T11:31:11","guid":{"rendered":"https:\/\/www.hematostat.net\/?p=17915"},"modified":"2024-02-07T12:51:36","modified_gmt":"2024-02-07T11:51:36","slug":"beigene-annonce-le-remboursement-de-son-ibtk-brukinsa-en-france-dans-3-indications","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/beigene-annonce-le-remboursement-de-son-ibtk-brukinsa-en-france-dans-3-indications\/","title":{"rendered":"BeiGene annonce le remboursement de son iBTK Brukinsa\u00ae en France dans 3 indications"},"content":{"rendered":"<p class=\"p1\">Paris, le 5 f\u00e9vrier 2024 \u2013 BeiGene France, filiale fran\u00e7aise de la biotech internationale sp\u00e9cialis\u00e9e en h\u00e9matologie et oncologie, a annonc\u00e9 la mise \u00e0 disposition en France du traitement<\/p>\n<p class=\"p1\">BRUKINSA\u00ae (zanubrutinib) \u00e0 la suite de la parution le 12 janvier 2024 du prix et du remboursement dans trois indications :<\/p>\n<p class=\"p1\">&#8211; Dans le traitement des patients adultes atteints d&#8217;une leuc\u00e9mie lympho\u00efde chronique (LLC) non pr\u00e9c\u00e9demment trait\u00e9s, uniquement :<\/p>\n<ul>\n<li class=\"p1\">Chez les patients ne pr\u00e9sentant pas de d\u00e9l\u00e9tion 17p et\/ou de mutation TP53 et in\u00e9ligibles<\/li>\n<\/ul>\n<p class=\"p1\">\u00e0 un traitement \u00e0 base de fludarabine \u00e0 pleine dose ;<\/p>\n<ul>\n<li class=\"p1\">Chez les patients pr\u00e9sentant une d\u00e9l\u00e9tion 17p et\/ou une mutation TP53 ;<\/li>\n<\/ul>\n<p class=\"p1\">&#8211; Dans le traitement des patients adultes atteints de LLC ayant re\u00e7u au moins un traitement ant\u00e9rieur ;<\/p>\n<p class=\"p1\">&#8211; En monoth\u00e9rapie dans le traitement de patients adultes atteints de lymphome de la zone marginale (LZM) ayant re\u00e7u au moins un traitement ant\u00e9rieur \u00e0 base d&#8217;anticorps anti-CD20 ;<\/p>\n<p>&#8211; En monoth\u00e9rapie dans le traitement de patients adultes atteints de macroglobulin\u00e9mie de Waldenstr\u00f6m (MW) qui ont re\u00e7u au moins un traitement ant\u00e9rieur.<\/p>\n<p class=\"p1\"><i>\u00ab Malgr\u00e9 des progr\u00e8s de prise en charge \u00e9vidents, les h\u00e9mopathies malignes repr\u00e9sentent toujours des <\/i><i>maladies graves avec une mortalit\u00e9 \u00e9lev\u00e9e : le besoin d\u2019innovations th\u00e9rapeutiques reste donc entier \u00bb a <\/i><i>expliqu\u00e9 Pr V\u00e9ronique Leblond, Professeur \u00c9m\u00e9rite \u00e0 la Sorbonne Universit\u00e9, Service d&#8217;H\u00e9matologie de <\/i><i>l\u2019H\u00f4pital de la Piti\u00e9 Salp\u00eatri\u00e8re \u00e0 Paris. \u00ab Le fait de disposer d\u2019un nouvel inhibiteur de BTK repr\u00e9sente ainsi <\/i><i>une excellente nouvelle. \u00bb<\/i><\/p>\n<p style=\"text-align: right;\"><em>D&#8217;apr\u00e8s un communiqu\u00e9 de presse de BeiGene le 5 f\u00e9vrier 2024.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Paris, le 5 f\u00e9vrier 2024 \u2013 BeiGene France, filiale fran\u00e7aise de la biotech internationale sp\u00e9cialis\u00e9e en h\u00e9matologie et oncologie, a annonc\u00e9 la mise \u00e0 disposition en France du traitement BRUKINSA\u00ae [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[441],"class_list":["post-17915","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-admin6779"],"aioseo_notices":[],"authors":[{"term_id":441,"user_id":1,"is_guest":0,"slug":"admin6779","display_name":"HematoStat.net","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/4f64711e55fa3c9401676697c4783cec15305a6f940a0f120048b6141a611347?s=96&d=mm&r=g","first_name":"HematoStat.net","last_name":"","user_url":"http:\/\/www.hematostat.net","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=17915"}],"version-history":[{"count":2,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17915\/revisions"}],"predecessor-version":[{"id":17920,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17915\/revisions\/17920"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=17915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=17915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=17915"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=17915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}